The APLC 2025 consensus recommendations on the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia

Cheung CYM 1 , Halim NAA 2 , Gan GG 3 , Wang Y 4 , Than H 2 , Jin J 5 Show all authors , Ko BS 6 , Lim SM 7 , Limvorapitak W 8 , Liu T 9 , Lui PL 10 , Ooi MGM 10 , Venkata SS 11 , Tantiworawit A 12 , Wong GC 2 , Yeh SP 13 , Yoo JH 14 , Ng AP 15

Affiliations 

  • 1 Queen Mary Hospital, Hong Kong, China
  • 2 Singapore General Hospital, Singapore, Singapore
  • 3 Department of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
  • 4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
  • 5 First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China
  • 6 National Taiwan University Hospital, Taipei, Taiwan
  • 7 Hospital Sultanah Aminah, Johor Bahru, Malaysia
  • 8 Thammasat University Hospital, Khlong Nueng, Thailand
  • 9 West China Hospital of Sichuan University, Chengdu, China
  • 10 National University Cancer Institute, Singapore, Singapore
  • 11 Tan Tock Seng Hospital, Singapore, Singapore
  • 12 Chiang Mai University Hospital, Chiang Mai, Thailand
  • 13 China Medical University Hospital, Taichung, Taiwan
  • 14 Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
  • 15 Peter MacCallum Cancer Centre, Melbourne, Australia
Leuk Lymphoma, 2026 Oct 30.
PMID: 42962083 DOI: 10.1080/10428194.2026.2743349

Abstract

The Asia-Pacific Leukemia Consortium (APLC) working group for Acute Lymphoblastic Leukemia (APLC ALLWG) recognized the critical need for standardized approaches to measurable residual disease (MRD) assessment and management in adult acute lymphoblastic leukemia (ALL). This paper presents consensus statements from APLC ALLWG experts addressing three key areas: (i) MRD assessment technologies and platforms; (ii) optimal timing for MRD evaluation across different patient populations; and (iii) clinical management strategies based on MRD levels. These evidence-based recommendations provide hematologists throughout the Asia-Pacific region with a structured framework for interpreting MRD data and making informed decisions to improve clinical outcomes in adult ALL patients.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications